Based on the fact that mice deficient in either IL-10 or the IL-10 receptor α or β chains develop spontaneous colitis and multiple anti-inflammatory functions in IBD (60, 119), after proving recombinant IL-10 is safe for human in clinical trial at early 1990s (153), rhuIL-10 was used to treat IBD patients in clinical trial in 2000. This evidence concerns the gene IL10 and inflammatory bowel disease.